Want to see PROK full AI Analyst Report?
PROK Stock Chart & Stats
$1.50
-$0.02(-1.32%)
At close: 4:00 PM EDT
$1.50
-$0.02(-1.32%)
Day’s Range― - ―
52-Week Range$1.45 - $3.48
Previous CloseN/A
Volume1.72M
Average Volume (3M)1.38M
Market Cap
$495.38M
Enterprise Value$1.32K
Total Cash (Recent Filing)$181.56M
Total Debt (Recent Filing)$2.39M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Nov 16, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding205,199,700
10 Day Avg. Volume1,177,473
30 Day Avg. Volume1,376,340
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.75Price Target Upside283.33% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$511.14K
Bulls Say, Bears Say
Bulls Say
Regulatory AlignmentFDA recognition of eGFR slope as an acceptable surrogate endpoint materially raises the program's regulatory clarity. This creates a defined accelerated approval path that can shorten time-to-market and reduce late-stage regulatory risk versus unclear endpoint strategies.
Phase 3 ExecutionCompleting enrollment substantially lowers execution risk tied to recruitment and timing. A statistically powered PROACT 1 and a clear readout timeline provide a durable catalyst window for regulatory submission and potential commercialization planning if results are positive.
Low Financial LeverageVery low debt reduces insolvency and interest-service risk, giving management flexibility in financing clinical activities. For a cash-consuming biotech, low leverage is a durable structural advantage versus peers with heavier debt burdens.
Bears Say
High Cash BurnSustained multi-hundred-million dollar cash outflows mean the company cannot self-fund development long-term. Persistent burn creates structural dependency on external capital, raising dilution risk and constraining strategic optionality ahead of potential commercialization.
Pre-commercial Revenue ProfileMinimal and volatile revenue combined with outsized losses indicate no recurring commercial sales. This underscores a business model that remains entirely development-stage, leaving long-term viability dependent on trial success and future reimbursement dynamics.
Negative EquityMulti-year negative shareholders' equity reflects accumulated deficits and weak retained earnings, complicating balance-sheet resilience. This structural weakness can limit financing options, affect covenant negotiations, and increase the likelihood of dilutive capital raises.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $1.45 and its highest was $3.48 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $495.38M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Nov 16, 2026 which is in 96 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on Aug 10, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.01.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.16.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 205,199,700 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.75 (283.33% Upside)
$5.75 (283.33% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 54.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.90%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.75
▲(283.33% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
47.55% Insiders
1.99% Mutual Funds
0.99% Other Institutional Investors
46.98% Public Companies and
Individual Investors